Hot therapy for cold agglutinin disease

摘要

In this issue of Blood, Berentsen et al report remarkably high response rates, long-term efficacy, and acceptable toxicity of rituximab with bendamustine in patients with primary cold agglutinin disease (CAD) evaluated in a prospective trial of the Nordic Group.